RT Journal Article SR Electronic T1 Ophthalmological outcome of 6.5 years children treated for retinopathy of prematurity: a Swedish register study JF British Journal of Ophthalmology JO Br J Ophthalmol FD BMJ Publishing Group Ltd. SP bjo-2022-322022 DO 10.1136/bjo-2022-322022 A1 Eva Larsson A1 Ann Hellström A1 Kristina Tornqvist A1 Agneta Wallin A1 Birgitta Sunnqvist A1 Karin Sandgren Hochhard A1 Pia Lundgren A1 Abbas Al-Hawasi A1 Kristina Teär Fahnehjelm A1 Lotta Gränse A1 Gerd Holmstrom YR 2023 UL http://bjo.bmj.com/content/early/2023/01/29/bjo-2022-322022.abstract AB Aims To determine the ophthalmological outcome at 6.5 years of age in children treated for retinopathy of prematurity (ROP), and registered in the national Swedish National Register for ROP register.Methods Data on ROP, treatment and ophthalmological outcome were retrieved from the register. Visual acuity (VA), refractive errors and strabismus, together with visual impairment (VI) and any significant eye problem, defined as VA >0.5 logarithm of the minimal angle of resolution (logMAR) and/or strabismus and/or any refractive error were analysed. Risk factors such as sex, gestational age (GA), birth weight SD score, number of treatments and retreatments, postnatal age and postmenstrual age at first treatment were analysed.Results Follow-up data were available in 232 of 270 children born between 2007 and 2014 who had been treated for ROP. VI (VA >0.5 logMAR) was found in 32 (14%), strabismus in 82 (38%), refractive errors in 114 (52%) and significant eye problem in 143 (65%) children. Retreatment was a risk factor for VI and refractive errors. Male sex and neonatal brain lesion were risk factors for strabismus. An additional week of GA at birth reduced the risk for refractive errors, strabismus and significant eye problems.Conclusion The results of the present study revealed a high number of eye problems in children treated for ROP, emphasising the need for long-term follow-up. Retreatment of ROP was a risk factor for VI, and emphasises the importance of an accurate first treatment for the long-term ophthalmological outcome.Data are available on reasonable request. The deidentified datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.